fgf21 antibody  (Boster Bio)

Journal: Gut and Liver

Article Title: Expression of Fibroblast Growth Factor 21 and β-Klotho Regulates Hepatic Fibrosis through the Nuclear Factor-κB and c-Jun N-Terminal Kinase Pathways

doi: 10.5009/gnl17443

Figure Lengend Snippet: Effects of IL-1β on β-Klotho and FGF21 in Huh-7 cells. Huh-7 cells were incubated with IL-1β for 6 hours. β-Klotho expression levels (A and G), protein kinase B (B), extracelluar signal-regulated kinases (C), JNK (D), IκBα (E), and FGF21 (F and G) were determined by immunoblotting. IL, interleukin; FGF, fibroblast growth factor; JNK, c-Jun N-terminal kinase.

Article Snippet: The lysates were subjected to Western blotting analysis under reducing conditions using previously validated human β-Klotho antibodies (R & D Systems), anti-phospho-Erk1/2, total Erk1/2, phospho-AKT, total AKT, phospho-JNK, and total JNK antibodies (Cell Signaling Technology, Danvers, MA, USA), phospho-IκBα, total IκBα, proliferating cell nuclear antigen (PCNA), and GAPDH antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and FGF21 antibody (Boster Biological Technology, Pleasanton, CA, USA).

Techniques: Incubation, Expressing

Journal: Gut and Liver

Article Title: Expression of Fibroblast Growth Factor 21 and β-Klotho Regulates Hepatic Fibrosis through the Nuclear Factor-κB and c-Jun N-Terminal Kinase Pathways

doi: 10.5009/gnl17443

Figure Lengend Snippet: FGF21 inhibits IL-1β-induced growth retardation of hepatocytes. Huh-7 cells were incubated with 10 ng/mL of IL-1β (A), 500 ng/mL of FGF21 (B), or IL-1β+FGF21 (C), after which the expression of β-Klotho and PCNA was determined. (D) IL-1β-treated Huh-7 cells were incubated with or without FGF21 in a dose-dependent manner. Cell viability was measured by an methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay. IL, interleukin; FGF, fibroblast growth factor; PCNA, proliferating cell nuclear antigen; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

Article Snippet: The lysates were subjected to Western blotting analysis under reducing conditions using previously validated human β-Klotho antibodies (R & D Systems), anti-phospho-Erk1/2, total Erk1/2, phospho-AKT, total AKT, phospho-JNK, and total JNK antibodies (Cell Signaling Technology, Danvers, MA, USA), phospho-IκBα, total IκBα, proliferating cell nuclear antigen (PCNA), and GAPDH antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and FGF21 antibody (Boster Biological Technology, Pleasanton, CA, USA).

Techniques: Incubation, Expressing, MTT Assay

Journal: Gut and Liver

Article Title: Expression of Fibroblast Growth Factor 21 and β-Klotho Regulates Hepatic Fibrosis through the Nuclear Factor-κB and c-Jun N-Terminal Kinase Pathways

doi: 10.5009/gnl17443

Figure Lengend Snippet: Analysis of serum FGF19 and FGF21 levels in patients with viral or alcoholic hepatitis. Serum levels of FGF19 (A) and FGF21 (B) were determined by enzyme-linked immunosorbent assay. G1 (F0–F1, n=10), G2 (F2–F3, n=10), G3 (F4A–F4C, n=15). FGF, fibroblast growth factor. *p

Article Snippet: The lysates were subjected to Western blotting analysis under reducing conditions using previously validated human β-Klotho antibodies (R & D Systems), anti-phospho-Erk1/2, total Erk1/2, phospho-AKT, total AKT, phospho-JNK, and total JNK antibodies (Cell Signaling Technology, Danvers, MA, USA), phospho-IκBα, total IκBα, proliferating cell nuclear antigen (PCNA), and GAPDH antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and FGF21 antibody (Boster Biological Technology, Pleasanton, CA, USA).

Techniques: Enzyme-linked Immunosorbent Assay